ImmuPharma PLC (LON:IMM)‘s stock had its “buy” rating reiterated by stock analysts at Northland Capital Partners in a report released on Thursday. They currently have a GBX 181 ($2.44) price objective on the stock. Northland Capital Partners’ price target points to a potential upside of 265.66% from the company’s previous close.

Separately, Northland Securities reiterated a “buy” rating and set a GBX 171 ($2.31) target price on shares of ImmuPharma PLC in a research report on Thursday, June 1st.

ImmuPharma PLC (LON IMM) opened at 49.50 on Thursday. The firm’s 50-day moving average is GBX 49.53 and its 200-day moving average is GBX 52.68. ImmuPharma PLC has a 1-year low of GBX 31.44 and a 1-year high of GBX 70.32. The firm’s market capitalization is GBX 65.60 million.

ILLEGAL ACTIVITY NOTICE: This report was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2017/09/23/immupharma-plc-imm-stock-rating-reaffirmed-by-northland-capital-partners.html.

ImmuPharma PLC Company Profile

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.

Receive News & Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.